Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

512

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Migraine Disorders
Interventions
DRUG

Lasmiditan

Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.

DRUG

Placebo

Placebo

Trial Locations (39)

1070

Brussels

3000

Leuven

3500

Hasselt

4000

Liège

4420

Montegnée

8000

Bruges

10117

Berlin

15706

Santiago de Compostela

20100

Turku

20246

Hamburg

25524

Itzehoe

28100

Pori

28329

Bremen

28922

Alcorcón

31008

Pamplona

31059

Toulouse

33007

Oviedo

33076

Bordeaux

33200

Tampere

40100

Jyväskylä

41013

Seville

41812

Erkelenz

45122

Essen

46021

Valencia

46701

Gandia

48129

Münster

50100

Mikkeli

65189

Wiesbaden

73033

Göppingen

75010

Paris

76031

Rouen

79106

Freiburg/Breisgau

80802

München

81377

München

00029 HUS

Helsinki

05850

Hyvinkää

06002

Nice

59 037

Lille

08036

Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CoLucid Pharmaceuticals

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT00883051 - Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment | Biotech Hunter | Biotech Hunter